Acute mercury toxicity modulates cytochrome P450, soluble epoxide hydrolase and their associated arachidonic acid metabolites in C57Bl/6 mouse heart.
Mercury exposure is associated with increased risk of cardiovascular disease and profound cardiotoxicity. However, the correlation between Hg(2+)-mediated toxicity and alteration in cardiac cytochrome P450s (Cyp) and their dependent arachidonic acid metabolites has never been investigated. Therefore, we investigated the effect of acute mercury toxicity on the expression of Cyp-epoxygenases and Cyp-ω-hydroxylases and their associated arachidonic acid metabolites in mice hearts. In addition, we examined the expression and activity of soluble epoxide hydrolase (sEH) as a key player in arachidonic acid metabolism pathway. Mercury toxicity was induced by a single intraperitoneal injection (IP) of 2.5 mg/kg of mercuric chloride (HgCl₂). Our results showed that mercury treatment caused a significant induction of the cardiac hypertrophy markers, atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP); in addition to Cyp1a1, Cyp1b1, Cyp2b9, Cyp2b10, Cyp2b19, Cyp2c29, Cyp2c38, Cyp4a10, Cyp4a12, Cyp4a14, Cyp4f13, Cyp4f15, Cyp4f16 and Cyp4f18 gene expression. Moreover, Hg(2+) significantly increased sEH protein expression and activity levels in hearts of mercury-treated mice, with a consequent decrease in 14,15-, and 11,12-epoxyeicosatrienoic acids (EETs) levels. Whereas the formation of 14,15-, 11,12-, 8,9-dihydroxyeicosatrienoic acids (DHETs) was significantly increased. In conclusion, acute Hg(2+) toxicity modulates the expression of several Cyp and sEH enzymes with a consequent decrease in the cardioprotective EETs which could represent a novel mechanism by which mercury causes progressive cardiotoxicity. Furthermore, inhibiting sEH might represent a novel therapeutic approach to prevent Hg(2+)-induced hypertrophy.
Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, T6G 2E1, AB, Canada.
Issa E A
IE
Amara
Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, T6G 2E1, AB, Canada.
Osama H
OH
Elshenawy
Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, T6G 2E1, AB, Canada.
Mohamed
M
Abdelrady
Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, T6G 2E1, AB, Canada; College of Pharmacy, Qatar University, Doha, Qatar. Electronic address: aelkadi@ualberta.ca.
Ayman O S
AO
El-Kadi
D015126:8,11,14-Eicosatrienoic Acid / Q000031:analogs & derivatives / Q000378:metabolism; D000818:Animals; D016718:Arachidonic Acid / Q000378:metabolism*; D009320:Atrial Natriuretic Factor / Q000378:metabolism; D015415:Biomarkers / Q000378:metabolism; D006332:Cardiomegaly / Q000139:chemically induced* / Q000201:enzymology / Q000235:genetics; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics / Q000378:metabolism*; D004851:Epoxide Hydrolases / Q000378:metabolism*; D015971:Gene Expression Regulation, Enzymologic / Q000187:drug effects; D006321:Heart / Q000187:drug effects*; D007274:Injections, Intraperitoneal; D007527:Isoenzymes; D008297:Male; D008627:Mercuric Chloride / Q000008:administration & dosage / Q000633:toxicity*; D051379:Mice; D008810:Mice, Inbred C57BL; D009206:Myocardium / Q000201:enzymology*; D020097:Natriuretic Peptide, Brain / Q000378:metabolism; D012333:RNA, Messenger / Q000378:metabolism
D015415:Biomarkers; D007527:Isoenzymes; D012333:RNA, Messenger; D020097:Natriuretic Peptide, Brain; D016718:Arachidonic Acid; D008627:Mercuric Chloride; C046783:11,12-epoxy-5,8,14-eicosatrienoic acid; C046782:14,15-epoxy-5,8,11-eicosatrienoic acid; D009320:Atrial Natriuretic Factor; D003577:Cytochrome P-450 Enzyme System; D004851:Epoxide Hydrolases; D015126:8,11,14-Eicosatrienoic Acid
Arachidonic acid metabolism; Cardiac hypertrophy; Cytochrome P450s; Mercury; Soluble epoxide hydrolase